Ventus Therapeutics Pyrazolyl Indazole cGAS Inhibitors Patent, Apr 23
Summary
Ventus Therapeutics U.S., Inc. filed patent application US20260108510A1 on October 17, 2025 (Application No. 19362297), covering pyrazolyl indazole cGAS inhibitor compounds of Formula (I), (II), and (III) and their pharmaceutically acceptable salts, tautomers, and isotopically labeled derivatives. The application, classified under CPC A61K 31/4985 and C07D 487/04, discloses methods of treatment for cGAS-related diseases and disorders using compounds of Formula (I) or (III), with Formula (II) compounds designated as tool compounds for binding, functional, and cellular assays. Inventors include Patrick Cyr, Ramsay Beveridge, Alexandre Côté, Yann Lamotte, and Audrey Dumoulin.
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
The USPTO published patent application US20260108510A1 covering pyrazolyl indazole compounds that function as cGAS (cyclic GMP-AMP synthase) inhibitors. The application discloses pharmaceutical compositions and methods of treatment for cGAS-related diseases and disorders, including the compound structures of Formula (I), (II), and (III), along with their salts, tautomers, and isotopically labeled derivatives. Ring A2 is specified as a monocyclic pyrazolyl ring.
Pharmaceutical companies and biotech firms engaged in cGAS/STING pathway research or developing therapies for autoimmune and inflammatory conditions should monitor this filing for potential freedom-to-operate implications. Competitors with overlapping cGAS inhibitor programs may need to evaluate the scope of the disclosed claims relative to their own compound portfolios.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF
Application US20260108510A1 Kind: A1 Apr 23, 2026
Assignee
Ventus Therapeutics U.S., Inc.
Inventors
Patrick Cyr, Ramsay Beveridge, Alexandre Côté, Yann Lamotte, Audrey Dumoulin
Abstract
The present disclosure relates to compounds of Formula (I), (II), and (III): and pharmaceutically acceptable salts, tautomers, and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, R6A, R6B, a and b are as defined herein, and Ring A2 is a monocyclic pyrazolyl ring, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I) or (III). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.
CPC Classifications
A61K 31/4985 C07D 487/04
Filing Date
2025-10-17
Application No.
19362297
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.